Johnson & Johnson beat expectations for its Q4 numbers on the strength of psoriasis treatments and drugs to treat cancer. However, the company also signaled sales could slow this year. J&J posted revenue of $20.4 billion and net income of $3.04 billion in Q4. (CNBC)

Eli Lilly conducted extensive market research about consumer preferences vis-a-vis pricing information before releasing the first drug ads that reference price data. Lina Shields, the company’s chief media officer, took MM&M behind the scenes of its pre-campaign decisions. (MM&M)

The cost of treatments for type 1 diabetes nearly doubled in the U.S. from 2012 to 2016, according to research from the nonprofit Health Care Cost Institute. The annual cost to treat type 1 diabetes was $5,705 in 2016, up from $2,864 in 2012. (Reuters)

TG Therapeutics said Tuesday that its umbralisib treatment for marginal zone lymphoma has been granted breakthrough status from the FDA, a month after an early stage study of the drug in combination with Johnson & Johnson’s Imbruvica showed positive results. MZL has no approved therapies. (Endpoints)

Editas founder Katrine Bosley is stepping down from the top job at the company after five years. Director Cynthia Collins has been picked to serve as Editas’ interim CEO as the company starts a search for a permanent replacement. (Endpoints)